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We describe a gonorrhoea case with combined high-
level azithromycin resistance and ceftriaxone resist-
ance. In February 2018, a heterosexual male was 
diagnosed with gonorrhoea in the United Kingdom 
following sexual intercourse with a locally resident 
female in Thailand and failed treatment with ceftriax-
one plus doxycycline and subsequently spectinomy-
cin. Resistance arose from two mechanisms combining 
for the first time in a genetic background similar to a 
commonly circulating strain. Urgent action is essential 
to prevent further spread.
Antimicrobial resistance in  Neisseria gonorrhoeae  is 
a major concern. Dual therapy with ceftriaxone and 
azithromycin, the last two mainstream agents to 
which  N. gonorrhoeae  remains largely susceptible, is 
widely recommended internationally [1]. We describe 
a case of urethral and pharyngeal infection with  N. 
gonorrhoeae  with combined high-level azithromycin 
resistance and ceftriaxone resistance. Previously no 
such cases have been reported.
Case description and microbiology
In February 2018, a heterosexual male presented to 
a sexual health clinic in the United Kingdom (UK) 
with a 4-day history of urethral discharge and dysu-
ria. He reported having had sexual intercourse 3 days 
earlier with a regular female partner in the UK. He 
also reported having had sex with a locally resident 
female in Thailand in January 2018; he had no history 
of sexually transmitted infections and no other past 
medical history. Examination revealed a creamy white 
urethral discharge, with 3 + pus cells and Gram-negative 
intracellular diplococci seen under microscopy, leading 
to a diagnosis of urethral gonorrhoea infection. He was 
treated with a single dose of intramuscular ceftriaxone 
1 g and oral doxycycline 100 mg twice daily for 7 days.
A urine nucleic acid amplification test (NAAT) was 
positive for  N. gonorrhoeae  and  Chlamydia trachoma-
tis negative. N. gonorrhoeae was cultured from a urethral 
swab. Antimicrobial susceptibility testing was under-
taken by M.I.C. Evaluator Strips (Oxoid, Basingstoke, 
UK), according to the manufacturer’s instructions, 
with results confirmed using Etest (BioMérieux, Marcy 
l’Etoile, France) at Public Health England, Colindale, 
UK and the WHO Collaborating Centre for Gonorrhoea 
and other STIs, Sweden. European Committee on 
Antimicrobial Susceptibility Testing resistance break-
points were used [2]. The minimum inhibitory concen-
trations (MICs) of nine antimicrobials are given in Table 
1and demonstrate high-level resistance to azithromycin 
(>  256 mg/L) and resistance to ceftriaxone (0.5 mg/L), 
as well as tetracycline (32 mg/L) and ciprofloxacin (> 32 
mg/L). The patient was recalled and during this visit, 13 
days after starting ceftriaxone/doxycycline treatment, 
his symptoms had resolved and a urine NAAT was neg-
ative for N. gonorrhoeae. However, given the previous 
antibiotic susceptibility profile, he was treated with a 
single dose of intramuscular spectinomycin (2 g). At a 
follow-up appointment, 20 days later, a urine NAAT was 
negative but a pharyngeal swab (omitted accidentally 
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at the prior visits; the patient was asymptomatic at 
this site) was culture-positive for N. gonorrhoeae  thus 
fulfilling international criteria for a verified treatment 
failure [3] as no further contact was reported with 
the Thai female following initial treatment. The same 
MICs were obtained from both cultured isolates from 
the case. Following this, the patient was treated with 
ertapenem (1 g) intravenously for 3 days. Subsequent 
NAAT and culture of urethral and pharyngeal swabs a 
further 21 days later were negative. The patient’s reg-
ular UK partner had negative vaginal and pharyngeal 
swab NAATs. We were unable to contact the patient’s 
partner from Thailand who the patient had initially met 
via a dating website.
Antimicrobial resistance determinants and 
sequence analysis
By combining short-read (Illumina, San Diego, 
California, United States of America) and long-read 
(Oxford Nanopore Technologies, Oxford, UK) sequence 
data a complete hybrid 2.17Mb assembly for each 
isolate was determined, these have been deposited, 
together with raw sequence data, in the European 
Nucleotide Archive (PRJEB26560; see supplement for 
details). Mapping sequence reads to one of these novel 
reference genomes as previously described [4], the 
sequences of the pre-treatment urethral (G97687) and 
the post-initial treatment pharyngeal (G7944) isolates 
from the case were indistinguishable i.e. they were 
consistent with acquisition from the same source at 
both anatomical sites. The isolates had a novel N. gon-
orrhoeae  multi-antigen sequence typing (NG-MAST) 
Table 1
Antimicrobial minimum inhibitory concentrations, Neisseria gonorrhoeae case imported from Thailand to England, 
February 2018
Antimicrobial MIC Interpretationa
Ceftriaxone 0.5 mg/L Resistant
Cefixime 2 mg/L Resistant
Azithromycin > 256 mg/L High-level resistant
Ciprofloxacin > 32 mg/L Resistant
Tetracycline 32 mg/L Resistant
Benzylpenicillin 1 mg/L intermediate susceptible
Spectinomycin 8 mg/L Susceptible
Gentamicin 2 mg/L No resistance breakpoint available (low value)
Ertapenem 0.032 mg/L No resistance breakpoint available (low value)
MIC: minimum inhibitory concentrations. 
a European Committee on Antimicrobial Susceptibility Testing resistance breakpoints were used [2].
Table 2
Antimicrobial resistance determinants present in isolates, Neisseria gonorrhoeae case imported from Thailand to England, 
February 2018
Gene Variant Mechanism Antimicrobials affected
23S rRNA A2059G, 4 copies Decreased macrolide binding to 50S ribosome AZM
penA FC428 mosaic penA - 100% identity Reduced β-lactam acylation of penicillin binding protein (PBP) 2 CRO, PEN
penB G120K, A121D Reduced influx through PorB1b CRO, PEN, TET
mtrR G45D, Promoter deletion Over-expression of MtrCDE efflux pump resulting in increased efflux AZM, CRO, PEN, TET
ponA L421P Reduced β-lactam acylation of PBP1 PEN
tetM Gene presence Prevents tetracycline binding to the 30S ribosome TET
rpsJ V57M Reduced affinity of 30S ribosome for tetracycline TET
gyrA S91F, D95A Reduced quinolone binding to DNA gyrase CIP
parC S87R Reduced quinolone binding to topoisomerase IV CIP
AZM: azithromycin; CIP: ciprofloxacin; CRO: ceftriaxone; PEN: benzylpenicillin; TET: tetracycline.
Resistance determinants as previously described [5] were searched for. No additional macAB, norM promoter variants; mtrR, pilQ mutations; 
or erm, mef, ere genes were identified. The FC428 penA allele has NCBI accession number LC113953.1.
3www.eurosurveillance.org
sequence type (ST), ST16848 determined  in silico  [4], 
and were assigned MLST 12039.
Antimicrobial resistance determinants were identi-
fied from the sequencing data as described previ-
ously using a combination of  de novo  assembly and 
mapping-based approaches [5]. The isolates from the 
case included an identical mosaic  penA  allele to that 
previously identified in the ceftriaxone-resistant FC428 
strain isolated in Japan in 2015, which also had a 
ceftriaxone MIC of 0.5 mg/L [6]. This mosaic penA allele 
contains two key ceftriaxone resistance mutations, 
A311V and T483S, but not the T316P mutation found 
in the more resistant H041 strain [7]. The isolates also 
had the A2059G mutation in all four 23S rRNA genes 
– the most commonly occurring mutation responsible 
for high-level azithromycin resistance [8]. Additional 
antimicrobial resistance determinants are summarised 
in Table 2. The isolate had a N. gonorrhoeae Sequence 
Typing for Antimicrobial Resistance (NG-STAR) type of 
996.
Based on reference-based mapping and correct-
ing for recombination [4], previously sequenced 
ceftriaxone-resistant N. gonorrhoeae isolates, including 
the FC428 sharing the same penA allele, differed from 
our case by >  1,500 single nucleotide polymorphisms 
(SNPs) (Figure 1).
We compared our isolates’ sequences to all pub-
licly available whole-genome sequenced  N. gonor-
rhoeae  isolates. There were 7,812 sequences available 
for comparison, including European and North 
American surveillance samples and samples from a 
global collection. Using a rapid k-mer based search 
(see supplement for details), we identified the 98 most 
closely related genomes to the two sequences identi-
fied in our case to determine a maximum-likelihood 
phylogeny (Figure 2). The phylogeny contains two deep 
clades, the top clade contains the sequences from our 
case, which is predominantly from NG-MAST ST4995 
and closely-related STs (collectively known as geno-
group G4995); our case differs from G4995 by approxi-
mately 400 SNPs. The most closely related genomes 
were within 45 SNPs and were obtained in China (isola-
tion dates unavailable) with additional genomes within 
54 and 71 SNPs from the UK (2014) and Japan (2015), 
respectively.  N. gonorrhoeae  evolves at 3.6 SNPs per 
genome per year [4] meaning that the most recent 
Figure 1
















The figure shows a recombination-corrected maximum-likelihood phylogeny based on mapping to the Neisseria gonorrhoeae NCCP11945 
reference genome. It shows the relationship between the case’s isolates’ sequences and previously sequenced N. gonorrhoeae ceftriaxone 
resistant isolates (from NCBI/ENA BioProjects PRJNA416507, PRJNA415047, PRJEB14020 and GenBank accession number NC_002946.2) [6,7,14-
17,19,21]. Isolates from the case are in bold and labelled with the identifiers used in the text.
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common ancestor of these strains is likely to be from 
several years earlier. These related sequences each 
contained four copies of the 23S rRNA A2059G mutation 
conferring high-level azithromycin resistance; however, 
all contained the ceftriaxone-susceptible penA II allele. 
No other sequence in the tree contained any of the 
three  penA  key mutations associated with ceftriaxone 
resistance i.e. A311V, T316P and T483S.
Discussion
This is the first reported ceftriaxone-resistant, high-
level azithromycin resistant  N. gonorrhoeae  isolate 
worldwide. The emergence of dual resistance to the 
last remaining mainstream treatment options poses 
serious challenges for the management and control 
of gonorrhoea infections globally. The strain was also 
resistant to ciprofloxacin and tetracycline. Although 
our case’s urethral infection was cleared with empirical 
ceftriaxone/doxycycline treatment, his asymptomatic 
pharyngeal infection failed treatment despite the 
relatively high dose of ceftriaxone used (1 g, compared 
to 250–500 mg frequently used) and the MIC just 
above the resistance breakpoint. This suggests that 
increased ceftriaxone dosing may not be adequate in 
similar cases. The case also failed spectinomycin treat-
ment despite in vitro susceptibility. The limited efficacy 
of spectinomycin [9], as well as gentamicin [10,11] in 
pharyngeal infection, has been previously described.
Figure 2
Phylogeny of the most closely related existing Neisseria gonorrhoeae genome sequences to the imported Neisseria 
gonorrhoeae case from Thailand to England, February 2018
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CRO-R: ceftriaxone resistant; HL-AziR: high-level azithromycin resistant.
The figure shows a recombination-corrected maximum-likelihood phylogeny based on mapping to a novel hybrid assembly of the case’s 
sequences (ENA Sample ERS2461487). It shows the relationship between isolate sequences identified from our case and the most closely 
genetically related previously sequenced Neisseria gonorrhoeae isolates. Sequences are labelled with country and year of isolation where 
available (obtained either from the European Nucleotide Archive or the sequence submitter); sequence run accession numbers are provided. 
Antimicrobial susceptibilities were inferred from available sequence data [5]. Isolates from the case are shown in bold and labelled with the 
identifiers used in the text. The NG-MAST genogroup G4995’s most recent common ancestor is indicated by an arrow.
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The first sustained national transmission of isolates 
with high-level resistance to azithromycin (MIC  ≥  256 
mg/L) has been recently documented in the UK [12], 
as well as a cluster of cases in Hawaii [13]. However, 
only a limited number of ceftriaxone-resistant isolates 
(MIC  ≥  0.25 mg/L) cases have been characterised in 
detail worldwide. These include strains H041/WHO-X 
(Japan 2009, ceftriaxone MIC 2–4 mg/L) [7], F89/WHO-Y 
(France and Spain 2010, 1–2 mg/L) [14,15], A8806/
WHO-Z (Australia 2013, 0.5 mg/L) [16], GU140106 (Japan 
2014, 0.5 mg/L) [17], a strain in Argentina 2014 (0.5 
mg/L) [18], and FC428 (Japan 2015, 0.5 mg/L) [6]. While 
the earlier reports were not associated with apparent 
sustained onward transmission, subsequent spread of 
strains closely related to FC428 have been reported in 
Canada [19], Denmark [20] and Australia [21] in 2017 
and are predominately associated with travel to south-
east Asia. However, these previous strains were either 
susceptible, intermediate or had low-level resistance 
to azithromycin with MICs of 0.25–1 mg/L. Six strains 
in a multi-institutional series from Japan (2000–2015) 
[22] and several isolates from a Chinese series (2013–
2016) [23] were ceftriaxone-resistant with MICs of 0.5 
mg/L, as well as a case from the United States in 2017 
[24]. In 2014, combined azithromycin and ceftriaxone 
treatment failure was reported in the UK, with MICs of 
1 and 0.25 mg/L respectively [25].
Dual resistance against recommended antibiotics for 
first-line treatment, including high-level azithromycin 
resistance, had not been reported until Public Health 
England issued an alert regarding this current case [26]. 
A similar public health alert has since been released 
by the Australian Department of Health, whereby they 
reported two further cases [27].
In our case, dual resistance arose via two known anti-
microbial resistance mechanisms, which combined in 
the same isolate for the first recorded time. Comparing 
our isolates with all previously genome sequenced  N. 
gonorrhoeaeisolates, we found that our isolates con-
tain the same penA allele found in FC428 from Japan in 
2015, but their overall genomes differ substantially (by 
>  1,500 SNPs). The isolates from our case were more 
closely related (circa 400 SNPs) to those from geno-
group G4995, which was the eighth most commonly 
circulating NG-MAST genogroup in Europe in 2013 [28]. 
To date, the spread of ceftriaxone-resistant strains 
has been limited, which is possibly due to the lim-
ited fitness of these strains. However, our isolate 
represents the concerning new combination of a cef-
triaxone resistant penA allele that has disseminated to 
several countries including Japan, Australia, Canada, 
and Denmark, together with high-level azithromycin 
resistance, in a genetic background similar to a 
successful and commonly circulating strain.
Conclusion
Combined high-level resistance to azithromycin and 
resistance to ceftriaxone poses a global public health 
threat. Greater access to resistance testing, including 
through the development of new molecular diagnos-
tics, is required to help guide treatment and ensure 
robust antimicrobial stewardship. This combined with 
increased use of test of cure, effective partner notifica-
tion and fast-tracked development of new treatments 
and ideally a gonococcal vaccine, requires urgent 
action. The treatment failure also illustrates the severe 
difficulties in effectively treating pharyngeal gonor-
rhoea, and enhanced focus on appropriate detection 
and treatment of pharyngeal gonorrhoea, including in 
heterosexual men and women, is essential. This case, 
taken together with previous reports, highlights the 
global nature of antimicrobial resistance in gonorrhoea 
and in particular the importance of transmission in 
south-east Asia where systematic surveillance to date 
has been relatively limited. International cooperation 
is key to ensuring that gonorrhoea remains a treatable 
infection.
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